Mather Group LLC. Increases Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Mather Group LLC. boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 83.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 769 shares of the medical research company’s stock after buying an additional 350 shares during the period. Mather Group LLC.’s holdings in IQVIA were worth $136,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of IQV. Brighton Jones LLC increased its position in shares of IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after acquiring an additional 2,537 shares during the period. Jones Financial Companies Lllp boosted its stake in shares of IQVIA by 57.0% during the 4th quarter. Jones Financial Companies Lllp now owns 1,215 shares of the medical research company’s stock worth $239,000 after acquiring an additional 441 shares in the last quarter. SBI Securities Co. Ltd. purchased a new stake in shares of IQVIA during the 4th quarter worth about $60,000. Assetmark Inc. boosted its stake in shares of IQVIA by 21,537.3% during the 4th quarter. Assetmark Inc. now owns 49,333 shares of the medical research company’s stock worth $9,694,000 after acquiring an additional 49,105 shares in the last quarter. Finally, Proficio Capital Partners LLC purchased a new position in IQVIA in the 4th quarter valued at about $29,091,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on IQV. Truist Financial decreased their target price on shares of IQVIA from $263.00 to $216.00 and set a “buy” rating on the stock in a research note on Thursday, April 10th. Redburn Partners set a $188.00 price target on shares of IQVIA in a report on Friday, May 23rd. Robert W. Baird dropped their target price on shares of IQVIA from $195.00 to $161.00 and set a “neutral” rating for the company in a report on Wednesday, May 7th. Barclays decreased their price target on shares of IQVIA from $170.00 to $165.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 7th. Finally, Mizuho decreased their price objective on shares of IQVIA from $210.00 to $190.00 and set an “outperform” rating for the company in a research report on Thursday, May 15th. Eight investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $226.32.

IQVIA Stock Performance

Shares of IQV opened at $164.24 on Friday. The firm’s 50 day moving average is $150.86 and its 200-day moving average is $173.16. The stock has a market capitalization of $28.41 billion, a P/E ratio of 22.38, a P/E/G ratio of 1.82 and a beta of 1.30. The company has a debt-to-equity ratio of 2.19, a current ratio of 0.82 and a quick ratio of 0.82. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $252.88.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.63 by $0.07. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. The firm had revenue of $3.83 billion for the quarter, compared to analysts’ expectations of $3.77 billion. During the same period in the previous year, the company posted $2.54 EPS. The company’s quarterly revenue was up 2.5% compared to the same quarter last year. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.